Basics BioMarin Pharmaceutical Inc. Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. IPO Date: August 1, 1999 Sector: Healthcare Industry: Biotech Market Cap: $10.33B Activated in VL: True Average Daily Range Avg Daily Range: $0.86 | 1.64% Avg Daily Range (30 D): $0.75 | 1.39% Avg Daily Range (90 D): $0.75 | 1.33% Institutional Daily Volume Avg Daily Volume: 1.21M Avg Daily Volume (30 D): 1.71M Avg Daily Volume (90 D): 1.73M Trade Size Avg Trade Size (Sh.): 104 Avg Trade Size (Sh.) (30 D): 52 Avg Trade Size (Sh.) (90 D): 55 Institutional Trades Total Inst.Trades: 23,791 Avg Inst. Trade: $3.56M Avg Inst. Trade (30 D): $6.14M Avg Inst. Trade (90 D): $5M Avg Inst. Trade Volume: .06M Avg Inst. Trades (Per Day): 5 Market Closing Trades Avg Closing Trade: $10.81M Avg Closing Trade (30 D): $20.24M Avg Closing Trade (90 D): $19.16M Avg Closing Volume: 135.31K     News Oct 7, 2025 @ 3:00 PM AAV Gene Therapy Market Size to Skyrocket at 40.1%... Source: Towards Healthcare Oct 1, 2025 @ 9:48 AM Pompe Disease Market Analysis Report 2025-2035: En... Source: Researchandmarkets.Com Aug 19, 2025 @ 4:08 AM Predicting the Next Rule Breaker Buyout Source: Rick Munarriz Aug 5, 2025 @ 5:11 PM BioMarin Discontinues Preclinical Drug Candidate, ... Source: Vandana Singh Aug 4, 2025 @ 10:07 PM BioMarin (BMRN) Q2 Revenue Jumps 16% Source: Jesterai Financials   TTM Q2 2025 Q1 2025 Basic EPS $3.44 $1.25 $.97 Diluted EPS $3.38 $1.23 $.95 Revenue $ 3.06B $ 825.41M $ 745.15M Gross Profit $ 2.44B $ 675.32M $ 593.59M Net Income / Loss $ 657.24M $ 240.53M $ 185.69M Operating Income / Loss $ 776.08M $ 276.89M $ 223.89M Cost of Revenue $ 626.24M $ 150.09M $ 151.56M Net Cash Flow $ 246.54M $ 168.08M $ 107.38M PE Ratio 0.00